{"id":"NCT03691779","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age","officialTitle":"A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-02","primaryCompletion":"2020-08-07","completion":"2020-08-07","firstPosted":"2018-10-02","resultsPosted":"2021-10-22","lastUpdate":"2021-10-22"},"enrollment":71,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"Part A: ELX/TEZ/IVA","type":"EXPERIMENTAL"},{"label":"Part B: ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF genotypes.","primaryOutcome":{"measure":"Part A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA","timeFrame":"Part A: Day 15","effectByArm":[{"arm":"Part A: ELX/TEZ/IVA","deltaMin":6.13,"sd":1.52}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":21,"countries":["United States","Australia","Canada","Ireland","United Kingdom"]},"refs":{"pmids":["37983082","33734030","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Cough","Headache","Pyrexia","Oropharyngeal pain","Nasal congestion"]}}